Tech Company Financing Transactions
Pearl Therapeutics Funding Round
On 2/1/2010, Pearl Therapeutics raised $15 million in Series C funding from 5AM Ventures, Clarus and New Leaf Venture Partners.
Transaction Overview
Company Name
Announced On
2/1/2010
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series C
Investors
Proceeds Purpose
We anticipate that this capital infusion and our planned Series C financing will provide us with sufficient funds to advance PT003 through all of the Phase 2b trials necessary to initiate the Phase 3 program.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
200 Saginaw Drive
Redwood City, CA 94063
USA
Redwood City, CA 94063
USA
Phone
Website
Email Address
Overview
Pearl Therapeutics is focused on developing a pipeline of novel andsuperior products for chronic respiratory disorders, providing patientswith advanced therapeutic options in familiar and well accepted dosageforms. The company has licensed advanced particle technology from NektarTherapeutics (Nasdaq: NKTR) for developing a series of products in selectedtherapeutic fields.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Charles Bramlage
Chief Medical Officer
Colin Reisner
Chief Scientific Officer
Sarvajna Dwivedi
VP - Bus. Development
Lyn Baranowski
VP - Finance
William Picht
VP - Product Management
Robert Schultz
VP - Regulatory Affairs
Michael Golden
Browse more venture capital transactions:
Prev: 2/1/2010: BlueKai venture capital transaction
Next: 2/2/2010: XL Hybrids venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs